Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

Scientists at UCSF combined advanced brain-network modeling, genetics, and imaging to reveal how tau protein travels through ...

Using brain gene expression maps from the Allen Human Brain Atlas, the researchers tested the degree to which Alzheimer’s risk genes explain the patterns of both actual and residual tau. This allowed ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

The study, which analyzed data on 1.2 million people with dementia, found improvements in five out of eight global regions ...

The Moore County Senior Enrichment Center will host a cognitive health talk on Thursday, July 17, 10 to 11:15 a.m. Information from the Alzheimer’s Association called Facts and Figures will ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope. “Alzheimer’s disease is a specific condition resulting from an abnormal biological ...

Time Course of Alzheimer's Disease Damage from the disease begins to accrue years or decades before any symptoms begin. A given individual presenting at age 70 might be expected to spend a decade ...

The study, by researchers at Rush Medical College in Chicago, includes county-level estimates of Alzheimer’s rates among adults age 65 and older in all 3,142 U.S. counties.